Creative Biolabs is a leading service provider of antibody discovery for clients around the world. Our excellent experts have developed a state-of-art platform for antibody specific to Enterococcus discovery. This platform, known as Anti-Bacteria Biomolecular Discovery, improves the quality and output of antibodies and peptides specific to Enterococcus based on a variety of advanced technologies such as hybridoma, phage display, peptide array, etc.
Enterococcus is a large genus of lactic acid bacteria of the phylum Firmicutes. Enterococci are Gram-positive cocci that often occur in pairs (diplococci) or short chain. The majority of clinical enterococcal infections are caused by E. faecalis and E. faecium. E. faecalis is considered to be more virulent while E. faecium is more likely to be antibiotic resistant. In order to combat enterococcal infections, it is an urgent need to identify novel therapeutic and prophylactic options, one such option being immunotherapy.
Fig. 1 Enterococcus sp. infection in pulmonary tissue.
Enterococcus cell wall is composed of different carbohydrates and glycoconjugates. Among these carbohydrate-containing antigens, lipoteichoic acid (LTA) and capsular polysaccharides are essential in the protection of enterococci against neutrophil-mediated killing. LTA has been shown as the main target of opsonic antibodies against two E. faecalis prototype strains (CPS-A and CPS-B). Besides, immune sera raised against capsular polysaccharide is protective in a mouse bacteremia model against another two E. faecalis prototype strains (CPS-C and CPS-D). These data suggests that LTA and capsular polysaccharides are promising targets for Enterococcus-specific antibody discovery.
Fig. 2 Model of the enterococcal cell wall (Hancock et al. 2014).
SagA is a major antigen secreted by E. faecium, and is essential for E. faecium growth. A study has indicated that E. faecium SagA protein induces opsonic antibodies in rabbits immunized with recombinant SagA protein. Similarily, antibodies against SagA are shown to exert a protective effect against vancomycin-resistant Enterococci in a mouse model of bacteraemia.
Antimicrobial peptides (AMPs) are increasing popularity as alternatives for treatment of bacterial infections. It has been reported that enterococcal peptide AS-48 displays a concentration-dependent bactericidal effect on E. faecalis subsp. liquefaciens S-47. More recently, buwchitin, a novel antimicrobial peptide was identified from a rumen bacterial metagenome library, and was proved to have an inhibitory effect against E. faecium. Creative Biolabs is skilled at the discovery of peptides targeting Enterococcus by means of diverse technologies such as the construction and screening peptide libraries, peptide array, etc.
With years of experience in the field of antibody discovery, Creative Biolabs guarantees to provide a high-quality service for the discovery of antibodies and peptides against Enterococcus for global customers. Our excellent AntInfectTM Platform is an industry revolution utilizing the world-leading technologies such as hybridoma technology, phage display, peptide array, etc. If you are interested in our services, please feel free to contact us for more information and a detailed quote.
Reference
